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Abstract 21 
In silico digestion of milk protein-derived peptides with gastrointestinal enzyme activities was 22 
used to predict the release of peptides with a Pro residue at position 2 from the N terminus. These 23 
peptides are known to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates. Five casein-24 
derived synthetic peptides (Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu, Tyr-Pro-Tyr-Tyr, Leu-25 
Pro-Tyr-Pro-Tyr and Ile-Pro-Ile) and a casein (CasH), whey (WPH) and lactoferrin hydrolysate 26 
(LFH) generated with gastrointestinal enzymes were incubated with DPP-IV at 37C for 18 or 24 27 
h. Peptide breakdown was evident following incubation with DPP-IV. Different modes of DPP-28 
IV inhibition were observed depending on the test compound. Ile-Pro-Ile-Gln-Tyr, Tyr-Pro-Tyr-29 
Tyr and Leu-Pro-Tyr-Pro-Tyr were substrate-, Leu-Pro-Leu-Pro-Leu and CasH were prodrug- 30 
while WPH and LFH were true DPP-IV inhibitors. These results are relevant for the bioactivity 31 
and bioavailability of functional foods targeting DPP-IV inhibition with potential blood glucose 32 
regulatory properties in humans. 33 
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1. Introduction 39 
Inhibition of dipeptidyl peptidase IV (DPP-IV) has been proposed as a new avenue for the 40 
treatment of Type 2 diabetes (T2D). DPP-IV is an ubiquitous enzyme which can be found in 41 
different locations of the body including the surface of various cells and in the circulation. It 42 
hydrolyses incretin hormones such as glucose dependent insulinotropic peptide (GIP) and 43 
glucagon-like polypeptide-1 (GLP-1). Those incretins can enhance insulin secretion from 44 
pancreatic beta cells in the presence of nutrients in vivo (Bjelke et al., 2006). The degradation of 45 
GLP-1 and GIP by DPP-IV results in a loss in the bioactive properties of these hormones. DPP-46 
IV drug inhibitors are utilized to prevent incretin degradation in vivo, thereby increasing their 47 
half-life (Bjelke et al., 2006). 48 
Various studies have highlighted the possibility of using food-derived proteins and peptides as 49 
a natural source of DPP-IV inhibitors (Hatanaka et al., 2012; Huang, Jao, Ho & Hsu, 2012; 50 
Lacroix & Li-Chan, 2012b). These sources notably include milk proteins (Lacroix & Li-Chan, 51 
2012a; Silveira, Martínez-Maqueda, Recio & Hernández-Ledesma, 2013; Tulipano, Sibilia, 52 
Caroli & Cocchi, 2011; Uchida, Ohshiba & Mogami, 2011; Uenishi, Kabuki, Seto, Serizawa & 53 
Nakajima, 2012). Casein and whey protein hydrolysates have been identified as DPP-IV 54 
inhibitors (Lacroix & Li-Chan, 2012a; Nongonierma & FitzGerald, 2013; Tulipano et al., 2011; 55 
Uenishi et al., 2012). Hydrolysates generated from -lactoglobulin (Lacroix & Li-Chan, 2013; 56 
Silveira et al., 2013; Uchida et al., 2011), α-lactalbumin (Lacroix & Li-Chan, 2013), bovine 57 
serum albumin (Lacroix & Li-Chan, 2013) and lactoferrin (Lacroix & Li-Chan, 2013; 58 
Nongonierma & FitzGerald, 2013) have also been identified as potent DPP-IV inhibitors. Various 59 
DPP-IV inhibitory peptide sequences have been reported in the literature (Lacroix & Li-Chan, 60 
2012b). The potent DPP-IV inhibitory peptides, diprotin A (Ile-Pro-Ile) and B (Val-Pro-Leu), 61 
originating from microbial cultures of Bacillus cereus, display half maximal inhibitory 62 
concentration (IC50) values in the µM range (Rahfeld, Schierborn, Hartrodt, Neubert & Heins, 63 
1991). Recently, different dipeptides from rice protein with a Pro residue at the C terminus have 64 
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been identified as DPP-IV inhibitors (Hatanaka et al., 2012). However, various dipeptide 65 
sequences without Pro residues have also been identified as potent DPP-IV inhibitors 66 
(Nongonierma & FitzGerald, 2013). Several food-derived DPP-IV inhibitory peptide sequences 67 
longer than 2 amino acid residues have also been reported in recent studies (Silveira et al., 2013; 68 
Tulipano et al., 2011; Uchida et al., 2011; Uenishi et al., 2012). 69 
It is recognised that peptides which act as inhibitors of key enzymes in metabolic pathways 70 
may have different susceptibilities to further cleavage on binding to these enzymes. For instance, 71 
it has been proposed that inhibition of angiotensin I converting enzyme (ACE), a key enzyme in 72 
blood pressure control, by peptide inhibitors could be classified into three main categories based 73 
on their stability toward ACE. Peptides displaying an inhibitor-type behaviour are not cleaved 74 
following incubation with ACE. Peptides with a prodrug-type behaviour are cleaved by ACE, 75 
resulting in the release of a “true” inhibitory peptide with a lower IC50 value compared to the 76 
parent peptide. The third category of peptides, which show a substrate-type behaviour, are 77 
cleaved following incubation with ACE, resulting in an increase in the IC50 value compared to the 78 
parent peptide (Fujita & Yoshikawa, 1999). It has been demonstrated that many DPP-IV 79 
inhibitory peptides behaved as substrates for this enzyme. Rahfeld et al. (1991) reported for the 80 
first time that diprotin A and B were substrates for DPP-IV. This result could have been 81 
anticipated as both peptides have the structural features of DPP-IV preferred substrates, where a 82 
Pro residue is located at the penultimate position (Kühn-Wache, Bär, Hoffmann, Wolf, Rahfeld & 83 
Demuth, 2011; Vanhoof, Goossens, De Meester, Hendriks & Scharpé, 1995). Milk proteins and 84 
particularly caseins are relatively rich in Pro residues, therefore, it could be anticipated that 85 
various peptide sequences showing structural characteristics of DPP-IV substrates may be 86 
released upon enzymatic hydrolysis of milk proteins. Lacroix and Li-Chan (2012a) hypothesised 87 
that DPP-IV inhibition by various milk protein hydrolysates may actually involve milk protein-88 
derived peptides behaving as DPP-IV substrates. 89 
A link between the secondary complications of T2D such as cardiovascular disease 90 
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(atherosclerosis, stroke and coronary heart disease) and oxidative stress has been proposed. It has 91 
been suggested that natural antioxidants may be used as adjuncts to therapeutic approaches to 92 
help in preventing cardiovascular complications induced by T2D (Xu, Tappia, Neki & Dhalla, 93 
2013). Milk proteins and peptides have been identified for their antioxidant properties. The 94 
utilization of anti-diabetic milk peptides/hydrolysates with additional antioxidant properties in the 95 
management of T2D has therefore been proposed (Nongonierma & FitzGerald, 2013). 96 
Earlier studies have demonstrated the cleavage of milk protein-derived peptides by DPP-IV. 97 
However, to our knowledge, no studies have shown that milk protein-derived peptides display a 98 
prodrug- or substrate-type of inhibition towards DPP-IV. The aim of this study was to predict the 99 
release of DPP-IV substrate–like peptide sequences (peptides having a penultimate Pro residue) 100 
by gastrointestinal enzymes using an in silico digestion of the major individual milk proteins. 101 
Several casein-derived sequences were then synthesized and incubated with DPP-IV in order to 102 
assess their stability to further hydrolysis by DPP-IV. The parent peptides and their breakdown 103 
products were then tested for their DPP-IV inhibitory and antioxidant potential. A similar 104 
approach was followed with milk protein hydrolysates generated with gastrointestinal enzymes. 105 
2. Materials and methods 106 
2.1. Reagents 107 
The synthetic peptides Leu-Pro, Tyr-Pro, Ile-Pro, Tyr-Tyr, Leu-Pro-Leu, Tyr-Pro-Tyr, Ile-Gln-108 
Tyr, Tyr-Pro-Tyr-Tyr, Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-Tyr were 109 
from Thermo Fisher Scientific (Ulm, Germany). Ile, Tyr, Leu, trifluoroacetic acid (TFA), 110 
tris(hydroxymethyl)aminomethane (TRIS), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 6-hydroxy-111 
2,5,7,8-tetramethylchromane-2-carboxylic acid (Trolox
TM
), Gly-Pro-pNA, diprotin A (Ile-Pro-112 
Ile), ethanol, porcine DPP-IV (≥ 10 units.mg-1 protein), high performance liquid chromatography 113 
(HPLC) grade water and acetonitrile (ACN) were obtained from Sigma Aldrich (Dublin, Ireland). 114 
Hydrochloric acid (HCl) and sodium hydroxide (NaOH) were from VWR (Dublin, Ireland). 115 
2.2. In silico digestion of individual milk proteins with gastrointestinal enzymes and peptide 116 
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digestion with DPP-IV 117 
In silico digestion of individual milk proteins was carried out with the peptide cutter program 118 
(ExPASy, 2011) using gastrointestinal enzymes (pepsin, trypsin and chymotrypsin). The different 119 
peptides released were then analysed for their potential to act as DPP-IV preferred substrates, i.e., 120 
peptides with a Pro residue at the penultimate position. Three casein-derived peptide sequences 121 
(Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-Tyr) which contained 122 
previously identified DPP-IV inhibitory peptides within their sequence were selected from the in 123 
silico digestion with gastrointestinal enzymes. Ile-Pro-Ile-Gln-Tyr contained the potent DPP-IV 124 
inhibitor Ile-Pro-Ile which has also been identified as a DPP-IV substrate (Rahfeld et al., 1991). 125 
In addition, its incubation with DPP-IV was predicted to release Ile-Pro, which has been 126 
identified as a DPP-IV inhibitor (Hatanaka et al., 2012). Digestion of Leu-Pro-Leu-Pro-Leu and 127 
Leu-Pro-Tyr-Pro-Tyr with DPP-IV would theoretically release the previously identified DPP-IV 128 
inhibitors Leu-Pro and Tyr-Pro (Hatanaka et al., 2012). Tyr-Pro-Tyr-Tyr (Casoxin B) was used 129 
for its structural similarities with Leu-Pro-Tyr-Pro-Tyr. The five peptide sequences were digested 130 
in silico with DPP-IV and the resulting peptide products were identified. 131 
2.3. Digestion of milk protein hydrolysates and peptides with DPP-IV 132 
Peptides with a Pro residue at the penultimate position (position 2), including Tyr-Pro-Tyr, 133 
Leu-Pro-Leu, Leu-Pro-Leu-Pro-Leu, Tyr-Pro-Tyr-Tyr, Leu-Pro-Tyr-Pro-Tyr, Ile-Pro-Ile-Gln-Tyr 134 
and Ile-Pro-Ile, were subjected to DPP-IV digestion. The peptides Ile-Gln-Tyr and Pro-Ile, which 135 
did not present structural features of DPP-IV substrates, were used as negative controls. Peptides 136 
were resuspended in 100 mM Tris-HCl buffer pH 8.0 at 10 mg.mL
-1
 and incubated at 37C for 18 137 
h with DPP-IV at two different enzyme to substrate ratios (E:S), 1 and 10 U DPP-IV: 1 g peptide. 138 
The control consisted of the peptide resuspended in 100 mM Tris-HCl buffer pH 8.0 at 10 139 
mg.mL
-1
 incubated at 37C for 18 h without DPP-IV. The enzyme was heat inactivated at 90C 140 
for 20 min, which resulted in complete inactivation of the enzyme as no DPP-IV activity was 141 
detected when the heat treated DPP-IV was subsequently incubated with Gly-Pro-pNA. In order 142 
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to check the retention of activity at the end of the reaction, DPP-IV was also incubated for 18 h at 143 
37C in 100 mM Tris-HCl buffer pH 8.0 without substrate. At the end of the incubation period, 144 
this sample was incubated with Gly-Pro-pNA and DPP-IV activity was determined. 145 
Milk protein hydrolysates derived from caseins, whey proteins and lactoferrin as described in 146 
Nongonierma and FitzGerald (2013) were used in this study. The hydrolysates were resuspended 147 
in 100 mM Tris-HCl buffer pH 8.0 at 10 mg.mL
-1
 (final concentration) and incubated at 37C for 148 
24 h with DPP-IV at an E:S of 0.2 and 2 U of DPP-IV.g
-1
of hydrolysate. The control consisted of 149 
the hydrolysates resuspended in 100 mM Tris-HCl buffer pH 8.0 and incubated at 37C for 24 h 150 
without DPP-IV. Hydrolysis with DPP-IV was carried out in duplicate (n=2). 151 
2.4. DPP-IV inhibition assay 152 
Diprotin A was resuspended in HPLC grade water at concentrations ranging from 12.5 × 10
-3
 153 
to 12.5 µg.mL
-1 
(final concentration), the other peptides and milk protein hydrolysates were 154 
dispersed at concentrations ranging from 12.5 × 10
-3
 to 1.25 mg.mL
-1
 (final concentration). The 155 
DPP-IV inhibition assay was carried out as described by Nongonierma and FitzGerald (2013). 156 
Briefly, the test samples (25L) were pipetted onto a 96 well microplate (Sarstedt, Dublin, 157 
Ireland) containing Gly-Pro-pNA, the reaction substrate (50 L, final concentration 0.2 mM). 158 
The negative control contained 100 mM Tris-HCl buffer pH 8.0 (25L) and the reaction 159 
substrate Gly-Pro-pNA. The reaction was initiated by the addition of DPP-IV (50 L, final 160 
concentration 0.0025 U.mL
-1
). All the reagents and samples were diluted in 100 mM Tris-HCl 161 
buffer pH 8.0. Diprotin A was used as a positive control. Each sample was analysed in triplicate. 162 
The microplate was incubated at 37C for 60 min in a microplate reader (Biotek Synergy HT, 163 
Winoosky, VT, USA), absorbance of the released pNA was monitored at 405 nm. The DPP-IV 164 
IC50 values (concentration of active compound required to observe 50 % DPP-IV inhibition) were 165 
determined by plotting the percentage inhibition as a function of the concentration of test 166 
compound. 167 
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Lineweaver and Burk analysis was used to study the mode of inhibition as described by 168 
Nongonierma and FitzGerald (2013). The initial rate of the reaction (pNA released from Gly-Pro-169 
pNA) was measured at different Gly-Pro-pNA concentrations ranging between 0.2 to 0.6 mM in 170 
the presence and absence of the DPP-IV peptide inhibitors at their IC50 concentration. The 171 
affinity constant (Km, determined without inhibitor), apparent affinity constant (Kapp, 172 
determined in the presence of DPP-IV inhibitor) and the maximum rate of the reaction (Vmax) 173 
were determined from the double reciprocal plots. 174 
2.5. DPPH radical scavenging assay 175 
The DPPH assay was used to determine the radical scavenging properties of the peptides 176 
which were dispersed in HPLC grade water at concentrations ranging from 1.25 × 10
-2
 to 2.5 177 
mg.mL
-1
. The DPPH scavenging assay was carried out essentially according to Nongonierma and 178 
FitzGerald (2013). Briefly, the test samples (50L) were pipetted onto a 96 well microplate 179 
containing 150 µL of a DPPH (final concentration 0.088 mM) solution in 50 % (v/v) ethanol. The 180 
microplate was incubated at 37C for 60 min in a microplate reader, absorbance of the DPPH 181 
radical was monitored at 517 nm. Each sample was analysed in triplicate. Trolox was used as a 182 
positive control. Scavenging of the DPPH radical was determined with respect to a control 183 
containing no scavenger (DPPH solution added with 50 L water). The DPPH scavenging EC50 184 
values (concentration of active compound required to observe 50 % DPPH scavenging) were 185 
determined by plotting the percentage DPPH scavenging as a function of the concentration of test 186 
compound. 187 
2.6. Reverse-phase ultra-performance liquid chromatography (RP-UPLC) of peptides and 188 
hydrolysates 189 
Profiles of different samples, including peptides and milk protein hydrolysates, before and 190 
after incubation with DPP-IV at 37C were determined by reverse-phase (RP) using an ultra-191 
performance liquid chromatograph (UPLC Acquity - Waters, Dublin, Ireland) equipped with a 192 
2.1 x 50 mm, 1.7 µm Acquity UPLC C18 BEH column mounted with a 0.2 µm inline filter 193 
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(Waters) as described by Nongonierma and FitzGerald (2012). All peptides, including the DPP-194 
IV substrate-like peptides and their predicted breakdown products were injected in triplicate 195 
(n=3) onto the UPLC column at different concentrations (25, 50, 100, 150, 200 and 250 µg.mL
-1
). 196 
Retention time of the standards was used to identify amino acids and peptides present in the 197 
samples obtained before and after incubation with DPP-IV. The calibration curves (peak area as a 198 
function of peptide concentration, R
2
 > 0.95) for all peptides were generated and used to quantify 199 
the amount of each amino acid and peptide present in the samples before and after incubation 200 
with DPP-IV. 201 
2.7. Statistical analysis 202 
Means comparison was carried out using a one way ANOVA followed by a Student Newman-203 
Keuls test using SPSS (version 9, SPSS Inc., Chicago, IL, USA) at a significance level P < 0.05. 204 
3. Results 205 
3.1. In silico gastrointestinal digestion of DPP-IV inhibitory peptides 206 
Of the different milk protein-derived peptides identified with DPP-IV preferred substrate 207 
features, three peptide sequences Ile-Pro-Ile-Gln-Tyr (κ-casein variant A, f26-30), Leu-Pro-Tyr-208 
Pro-Tyr (κ-casein variant A, f56-60) and Leu-Pro-Leu-Pro-Leu (β-casein variant A2, f135-139) 209 
were chosen for this study. These were selected on the basis that they contained previously 210 
identified DPP-IV inhibitory peptides which may be released during DPP-IV digestion. In 211 
addition, Tyr-Pro-Tyr-Tyr (κ-casein variant A, f58-61) which has previously been identified as 212 
casoxin B (Chiba, Tani & Yoshikawa, 1989) and diprotin A (Ile-Pro-Ile, κ-casein variant A, f26-213 
28) were also included in this study. Ile-Pro-Ile, a well-known DPP-IV inhibitor, was used as a 214 
positive control as it has previously been identified as a DPP-IV substrate (Rahfeld et al., 1991). 215 
In silico digestion of these peptide sequences by DPP-IV allowed prediction of the potential 216 
breakdown products. The possible DPP-IV cleavage sites on the peptides are illustrated in Fig. 1. 217 
This analysis predicted that digestion of Ile-Pro-Ile-Gln-Tyr with DPP-IV would yield Ile-Pro and 218 
Ile-Gln-Tyr; Leu-Pro-Leu-Pro-Leu was predicted to yield Leu-Pro, Leu-Pro-Leu, and Leu; Leu-219 
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Pro-Tyr-Pro-Tyr was predicted to yield Leu-Pro, Tyr-Pro-Tyr, Tyr-Pro and Tyr; Tyr-Pro-Tyr-Tyr 220 
was predicted to yield Tyr-Pro and Tyr-Tyr while Ile-Pro-Ile was predicted to yield Ile-Pro and 221 
Ile. The five parent peptides and their predicted breakdown products were investigated for their 222 
DPP-IV inhibitory properties and their further susceptibility to cleavage by DPP-IV in vitro. 223 
3.2. DPP-IV inhibition and antioxidant activity of the milk protein-derived peptides 224 
Of the twelve peptides tested, ten (Leu-Pro, Tyr-Pro, Ile-Pro, Ile-Pro-Ile, Leu-Pro-Leu, Tyr-225 
Pro-Tyr, Tyr-Pro-Tyr-Tyr, Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-Tyr) 226 
were able to inhibit DPP-IV and two peptides were found to be inactive (Tyr-Tyr and Ile-Gln-227 
Tyr). The IC50 for the ten DPP-IV inhibitory peptides identified was determined (Table 1). The 228 
lowest IC50 value was observed for Ile-Pro-Ile (3.4 ± 0.1 µM), which was ten times lower than 229 
that of Ile-Pro-Ile-Gln-Tyr (35.2 ± 1.8 µM). The least potent compound studied herein was Leu-230 
Pro (712.5 ± 11.0 µM), which was ~ 200 times less potent than Ile-Pro-Ile. 231 
The mode of DPP-IV inhibition for the peptides was determined using the Lineweaver and 232 
Burk representation. The Lineweaver and Burk double reciprocal plots for Ile-Pro-Ile, Ile-Pro-Ile-233 
Gln-Tyr, Leu-Pro-Leu-Pro-Leu, Leu-Pro-Tyr-Pro-Tyr, Tyr-Pro-Tyr and Leu-Pro are illustrated in 234 
supplementary Fig. S1. For all peptides studied, there was no significant difference for Vmax 235 
determined with or without inhibitor (P ≥ 0.05), whereas Km was significantly different (P < 236 
0.05) from Kapp. These results suggested that all DPP-IV inhibitory peptides studied herein were 237 
competitive inhibitors of DPP-IV and therefore could directly bind to its active site. 238 
The antioxidant activity of the twelve peptides was evaluated by determining their ability to 239 
scavenge the DPPH radical. Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Tyr-Pro-Tyr, Tyr-Pro-Tyr-Tyr, Tyr-240 
Pro-Tyr and Tyr-Tyr were able to scavenge DPPH (Table 1). The other peptides did not show any 241 
scavenging activity toward DPPH radicals. The antioxidant potency of the peptides was evaluated 242 
by determining their EC50 value. The EC50 values were relatively high suggesting that these 243 
peptides did not have good antioxidant properties at least in vitro. 244 
3.3. Degradation of milk protein-derived peptides and milk protein hydrolysates following 245 
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incubation with DPP-IV 246 
Peptides with DPP-IV preferred substrate features (Ile-Pro-Ile, Leu-Pro-Tyr-Pro-Tyr, Leu-Pro-247 
Leu-Pro-Leu, Ile-Pro-Ile-Gln-Tyr, Tyr-Pro-Tyr-Tyr, Leu-Pro-Leu and Tyr-Pro-Tyr) were 248 
incubated with DPP-IV at a low and high E:S. After 18 h incubation at 37C with DPP-IV, all 249 
peptides were cleaved by the enzyme with the exception of Ile-Gln-Tyr and Pro-Ile (the negative 250 
controls) which in theory could not be cleaved by DPP-IV. It was found at the end of the 251 
incubation that DPP-IV was still active as 69.3  2.9 % DPP-IV activity was found. The RP-252 
UPLC profiles for Ile-Pro-Ile, Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-253 
Tyr incubated at the low and high E:S are illustrated on Fig. 2. The RP-UPLC profiles show that 254 
these peptides were cleaved to release their predicted breakdown products as per in silico 255 
digestion with DPP-IV (section 3.1.). As expected peptide breakdown was more pronounced at 256 
the high compared to the low E:S. The same results were found with Tyr-Pro-Tyr-Tyr, Tyr-Pro-257 
Tyr and Leu-Pro-Leu (data not shown). 258 
Quantification of the peptides in each sample was carried out using the response factors from 259 
the calibration curves determined for each individual peptide and amino-acid. The concentration 260 
of amino acids and peptides present in each sample is shown in Table 2. As expected, breakdown 261 
of the parent peptide was higher at the high compared to the low E:S. The mass balance of 262 
peptides generated during DPP-IV hydrolysis agreed with the concentration of parent peptide 263 
cleaved. Some components were not detected in the hydrolysed samples, this was due to the 264 
amount of amino acids or peptides being below the detection threshold. Differences were seen in 265 
the extent of peptide breakdown depending on the sequence of the parent peptide. At the high 266 
E:S, Tyr-Pro-Tyr-Tyr and Tyr-Pro-Tyr were completely cleaved and could not be detected after 267 
18 h incubation. In contrast, modest peptide breakdown was seen with Ile-Pro-Ile with less than 268 
10 % (w/w) of this peptide being cleaved at high E:S. 269 
Three milk protein hydrolysates studied herein which have previously been shown to be DPP-270 
IV inhibitors (Nongonierma & FitzGerald, 2013) were incubated with DPP-IV. The RP-UPLC 271 
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profiles for the high E:S digests are illustrated on supplementary Fig. S2. Slight differences were 272 
seen on the RP-UPLC profiles of the casein hydrolysate (CasH) before and after incubation with 273 
DPP-IV at 2, 20, 21 and 28 min retention times, where peptide peaks did not match between the 274 
control and the hydrolysate incubated with DPP-IV (supplementary Fig. S2 a). For the whey 275 
protein hydrolysate (WPH), one peak eluting at 15 min was absent from the hydrolysate after 276 
incubation with DPP-IV (supplementary Fig. S2 b). In the case of the lactoferrin hydrolysate 277 
(LFH), slight differences were seen at 3 and 9 min between the control and after incubation with 278 
DPP-IV (supplementary Fig. S2 c). 279 
Overall, incubation of the individual peptides with DPP-IV induced major changes in the 280 
peptide composition, whereas for the milk protein hydrolysate, only minor modifications were 281 
seen. 282 
3.4. DPP-IV inhibitory properties of milk protein-derived peptides and milk protein hydrolysates 283 
following incubation with DPP-IV 284 
The IC50 values for the peptides pre and post DPP-IV hydrolysis was evaluated to study the 285 
impact of peptide breakdown on the bioactive properties (Table 3). The IC50 value of the control 286 
samples were similar to the values previously reported for these peptides (Table 1), suggesting 287 
that the bioactive properties of these peptides were not altered following incubation at 37C for 288 
18 h. In addition, the RP-UPLC of the peptides in the control and freshly prepared peptides did 289 
not differ (data not shown), suggesting that the peptides were not degraded during incubation in 290 
the controls. For most peptides, there was no significant difference (P ≥ 0.05) in terms of IC50 291 
value between the control and the low E:S sample, with the exception of Leu-Pro-Leu-Pro-Leu. 292 
Leu-Pro-Leu-Pro-Leu had a significantly (P < 0.05) lower IC50 value at the low E:S compared to 293 
the control. For all peptides, incubation with DPP-IV at the high E:S resulted in a significant 294 
increase (P < 0.05) in the IC50 value compared to the control and the low E:S sample. However, 295 
this was not seen for Leu-Pro-Leu-Pro-Leu where the IC50 value significantly decreased (P < 296 
0.05) following incubation with DPP-IV and no significant difference (P ≥ 0.05) was seen 297 
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between the IC50 values at the low and high E:S. 298 
The IC50 values for the milk protein hydrolysates incubated with DPP-IV at a high and low 299 
E:S were determined (Fig. 3). There was no significant difference (P ≥ 0.05) between the IC50 300 
value of the three hydrolysate controls. Following incubation with DPP-IV, no significant 301 
differences in terms of IC50 values were found for WPH and LFH between the control and the 302 
high and low E:S digests. In contrast, for CasH, samples incubated with DPP-IV displayed a 303 
significantly lower (P < 0.05) IC50 value compared to CasH control. There was no significant 304 
difference (P ≥ 0.05) between CasH incubated at high or low E:S. 305 
4. Discussion 306 
This study has demonstrated that milk protein-derived peptides, with a Pro at position 2, 307 
predicted to be released by gastrointestinal enzymes could act as DPP-IV inhibitors, involving a 308 
substrate or prodrug mode of inhibition. With both substrate or prodrug modes of inhibition, the 309 
starting peptides are susceptible to further DPP-IV cleavage, resulting in the release of more or 310 
less potent peptide inhibitors as compared to the parent peptide. All peptides studied herein were 311 
competitive inhibitors, suggesting a direct interaction of the peptides with the active site of DPP-312 
IV. 313 
To our knowledge, of the different peptides studied, only Ile-Pro-Ile, Ile-Pro, Tyr-Pro and Leu-314 
Pro have previously been identified for their DPP-IV inhibitory properties (Hatanaka et al., 315 
2012). In agreement with the results of Hatanaka et al. (2012), Ile-Pro also displayed a lower IC50 316 
value compared to Leu-Pro (149.6  6.1 and 712.5  11.0 µM, respectively, Table 1). In addition, 317 
Ile-Pro was about 6 times more potent than Leu-Pro, which is of the same order as the values 318 
reported in Table 1. In contrast, we found that Tyr-Pro was a more potent DPP-IV inhibitor than 319 
Leu-Pro, whereas Hatanaka et al. (2012) reported the opposite trend. 320 
Relatively potent DPP-IV inhibitors displaying a substrate-type inhibition have been reported 321 
in the literature. The well-known inhibitors diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) 322 
isolated from microbial cultures have previously been shown to behave as DPP-IV substrates 323 
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(Rahfeld et al., 1991). Other DPP-IV inhibitory peptides isolated from casein with a Pro at the 324 
penultimate position, have recently been identified, these include Leu-Pro-Gln-Asn-Ile-Pro-Pro-325 
Leu, Leu-Pro-Gln and Val-Pro-Ile-Thr-Pro-Thr-Leu with IC50 values of 46, 82 and 110 µM, 326 
respectively (Uenishi et al., 2012). Similarly, Ile-Pro-Ala (Tulipano et al., 2011) and Ile-Pro-Ala-327 
Val-Phe (Silveira et al., 2013) were isolated from β-lactoglobulin, with DPP-IV IC50 values of 49 328 
and 45 µM, respectively. Results obtained from DPP-IV inhibitory potency correlated with the 329 
composition of the samples, with the overall IC50 value being governed by the amount of the most 330 
potent peptide within the sample (Table 2 and 3). Similar results have previously been reported 331 
by Hatanaka et al. (2012) with Diprotin A (Ile-Pro-Ile) having an IC50 value twice as low as its 332 
breakdown product Ile-Pro (0.21 ± 0.01 mM and 0.41 ± 0.07 mM, respectively). For illustration, 333 
in the case of Tyr-Pro-Tyr and Tyr-Pro-Tyr-Tyr incubated at a high DPP-IV E:S, all the parent 334 
peptide was degraded. As a consequence, these samples only contained Tyr-Pro as DPP-IV 335 
inhibitory peptide. Interestingly, the IC50 value for Tyr-Pro-Tyr and Tyr-Pro-Tyr-Tyr incubated at 336 
high E:S of DPP-IV (523.4  31.9 and 783.7  50.6 µM, respectively, Table 3) was of the same 337 
order as that of Tyr-Pro (658.1  8.0 µM, Table 1). 338 
To our knowledge, no study has identified milk protein-derived peptides with a prodrug-type 339 
behavior for DPP-IV inhibition. One peptide, Leu-Pro-Leu-Pro-Leu, had a different behaviour 340 
from the other peptides studied herein, showing a decrease in the IC50 value following incubation 341 
at low and high E:S as compared to the control (Table 3). This peptide therefore displayed a 342 
prodrug-type inhibition according to the classification established by Fujita & Yoshikawa (1999). 343 
In the sample containing Leu-Pro-Leu-Pro-Leu incubated with low and high E:S, significant 344 
amounts of Leu-Pro-Leu were found (Table 2). This peptide is about 30 % more potent than Leu-345 
Pro-Leu-Pro-Leu and three times more potent than Leu-Pro, which explains the overall decrease 346 
in IC50 value seen following incubation of Leu-Pro-Leu-Pro-Leu with DPP-IV. 347 
Relatively high amounts of Leu-Pro-Leu and Tyr-Pro-Tyr, which could be substrates for DPP-348 
IV were also found with the parent peptides Leu-Pro-Leu-Pro-Leu and Tyr-Pro-Tyr-Pro-Tyr, 349 
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respectively, incubated with DPP-IV at high E:S. The susceptibility of Leu-Pro-Leu and Tyr-Pro-350 
Tyr to DPP-IV cleavage varied when these sequences were encrypted in a larger peptide (Leu-351 
Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-Tyr, respectively). At the high E:S, around 35 % of Tyr-352 
Pro-Tyr was cleaved from Leu-Pro-Tyr-Pro-Tyr, whereas 100 % of Tyr-Pro-Tyr was cleaved 353 
with DPP-IV. For Leu-Pro-Leu incubated with DPP-IV, more than 75 % was cleaved whereas 30 354 
% Leu-Pro-Leu was cleaved when Leu-Pro-Leu-Pro-Leu was incubated with DPP-IV at the high 355 
E:S. These differences may arise from the inhibition exerted by the parent peptide (Leu-Pro-Leu-356 
Pro-Leu or Leu-Pro-Tyr-Pro-Tyr) on DPP-IV, which may have blocked further cleavage of Tyr-357 
Pro-Tyr and Leu-Pro-Leu. This is further supported by the fact that the more potent DPP-IV 358 
inhibitory peptides (i.e. Ile-Pro-Ile, Ile-Pro-Ile-Gln-Tyr and Leu-Pro-Tyr-Pro-Tyr, Table 1) 359 
studied herein were generally cleaved to a lesser extent by DPP-IV (Table 2 and Fig. 2). 360 
For the whey protein-derived hydrolysates (WPH and LFH), preincubation with DPP-IV did 361 
not affect the DPP-IV inhibitory properties of the samples (Fig. 3). This was in agreement with 362 
the fact that the peptide profile for these samples was essentially unaffected by incubation with 363 
DPP-IV (supplementary Fig. S2). However, with CasH, more obvious modifications were seen in 364 
the peptide profile, which resulted in a significant decrease in the DPP-IV inhibitory properties. 365 
Differences observed between whey proteins and caseins may come from the fact that caseins 366 
contain higher amounts of Pro residues on a weight basis compared to whey. In addition, a higher 367 
number of peptides with a Pro at the penultimate position were identified with the in silico 368 
approach used herein for the caseins (αs1-, αs2-, β- and κ-casein) as compared to the whey proteins 369 
(β-lactoglobulin and α-lactalbumin). The significant decrease in the IC50 value observed with 370 
CasH following incubation with DPP-IV may be explained by the fact that it may contain 371 
prodrug-type DPP-IV inhibitory peptides. Peptide peaks eluting at the same retention time as 372 
Leu-Pro-Leu-Pro-Leu (17.9 min) and Leu-Pro-Leu (12.3 min) were seen on the RP-UPLC profile 373 
of CasH. However, there was no difference in peak areas between the control and the high E:S 374 
digest of CasH, suggesting that these peptides may not be responsible for the decreased IC50 375 
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value. However, several other peptides which have not been studied herein may be responsible 376 
for this effect. Mass spectrometric identification of the peptides within CasH may help to better 377 
understand the effect of DPP-IV pre-digestion on the overall DPP-IV inhibitory properties of the 378 
casein hydrolysate. 379 
To assess if the peptides studied herein also had the potential to reduce oxidative stress in 380 
T2D, their antioxidant activity was studied. The peptides evaluated herein only had a modest 381 
DPPH scavenging activity. The EC50 value for DPPH scavenging by the casein-derived peptide 382 
Tyr-Pro-Tyr-Pro-Glu-Leu was 98 M while it was 23.3 M for carnosine (Ala-His) (Suetsuna, 383 
Ukeda & Ochi, 2000). EC50 values of 242 and 654 M have been reported for Trp-Val and Val-384 
Trp, respectively (Nongonierma & FitzGerald, 2013). 385 
A wide range of biologically active peptides, including immunomodulatory, neuro- and vaso- 386 
active peptides, may be cleaved in vivo by DPP-IV resulting, in some cases, in the alteration of 387 
their biological activity (Vanhoof et al., 1995). In agreement with our results, relatively long 388 
incubation times with DPP-IV were required to achieve significant cleavage of the substrate. For 389 
instance, with [(Xaa-Pro)n]−[drug] conjugates, it has been shown that up to 92 % of the 390 
conjugates were cleaved by DPP-IV following a 24 h incubation period (García-Aparicio et al., 391 
2006). Cleavage of the milk protein-derived peptide, β-casomorphin (f1-5) (Tyr-Pro-Phe-Pro-392 
Gly), by DPP-IV from renal brush border membrane has been demonstrated (Miyamoto, 393 
Ganapathy, Barlas, Neubert, Barth & Leibach, 1987; Tiruppathi, Miyamoto, Ganapathy, Roesel, 394 
Whitford & Leibach, 1990). In addition, it was also shown that cleavage of Pro containing 395 
peptides and gliadin, a Pro rich protein, also occurred with DPP-IV from intestinal brush border 396 
membrane of rat (Tiruppathi, Miyamoto, Ganapathy & Leibach, 1993). It was also demonstrated 397 
that Leu-Pro-Gly-Gly was degraded in Leu-Pro and Gly-Gly by DPP-IV located in the intestinal 398 
brush border membrane of rat (Morita, Chung, Freeman, Erickson, Sleisenger & Kim, 1983). 399 
Based on the available scientific evidence, it is anticipated that the results obtained in vitro with 400 
the milk protein-derived peptides studied herein may also translate in vivo. The different milk 401 
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protein-derived peptides studied herein may be further degraded by DPP-IV in the 402 
gastrointestinal tract to release amino acids and smaller peptides as predicted by the in silico 403 
digestion with DPP-IV (Fig. 1). 404 
Degradation of Pro containing peptides by DPP-IV located in the intestinal brush border 405 
membrane in vivo has been shown to directly affect absorption of peptides. Morita et al. (1983) 406 
have shown that ileal absorption rate of the constitutive amino acids of Leu-Pro-Gly-Gly (i.e. 407 
Leu, Pro and Gly) and Leu-Pro and Gly-Gly was faster than that of the tetrapeptide. Relatively 408 
high levels of DPP-IV (1.03 g.mL
-1
) have been identified in the serum of humans (Cuchacovich, 409 
Gatica, Pizzo & Gonzalez-Gronow, 2001). If they can cross the gut barrier, it is anticipated that 410 
the short peptides studied herein (Leu-Pro-Leu and Tyr-Pro-Tyr) may be degraded into Leu-Pro 411 
and Tyr-Pro. Leu-Pro and Tyr-Pro could in turn inhibit DPP-IV in the circulation. The peptide 412 
sequences studied herein are of relevance to multi-site targeting for DPP-IV inhibition. They may 413 
display their DPP-IV inhibitory potential directly in the gastrointestinal tract where they may be 414 
degraded by intestinal brush border DPP-IV (Tiruppathi et al., 1993). This in turn will release 415 
shorter peptides which are better candidates for intestinal permeation possibly allowing these to 416 
reach the circulation where they may further display their DPP-IV inhibitory properties. Although 417 
the IC50 value of the larger peptides was generally found to be lower than that of the shorter 418 
peptides studied herein, the IC50 values for shorter peptides indicate that these are still moderately 419 
potent inhibitors of DPP-IV (Table 1). 420 
 421 
Conclusion 422 
Milk protein-derived peptides which have been predicted to be released by gastrointestinal 423 
enzyme activities have been shown to behave as substrate- or prodrug-type inhibitors of DPP-IV. 424 
Besides their DPP-IV inhibitory properties, which make them interesting candidates for 425 
protecting incretins against DPP-IV cleavage in the gastrointestinal tract, the instability of these 426 
peptides may be further exploited. Cleavage of these peptide sequences by DPP-IV was shown to 427 
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release peptides which were in some cases more or less potent DPP-IV inhibitors. It is anticipated 428 
that such peptides, owing to their small size and relatively high hydrophobicity may be good 429 
candidates for intestinal absorption, thereby, allowing them to reach the circulation where they 430 
may display their bioactive properties. Validation of these results in vivo is still required, 431 
however, based on numerous studies conducted in vivo with peptides showing DPP-IV substrate-432 
like features, it is anticipated that similar trends may be found in vivo. To our understanding, the 433 
results presented herein are relevant to the management of type 2 diabetes with functional foods 434 
involving multi-target sites for DPP-IV inhibition in humans. 435 
436 
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Table 1 Peptide concentration inducing 50 % inhibition (IC50) for dipeptidyl peptidase IV (DPP-IV) and 
concentration of peptide required to observe 50 % 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging (EC50) in 
the presence of milk protein-derived peptides. 
 
Peptide sequence DPP IV IC50 (μM)
*
 DPPH EC50 (mM)
*
 
IPI (diprotin A) 3.4 ± 0.1
a
 nd 
IPIQY 35.2 ± 1.8
b
 4.18 ± 0.61 
LPYPY 108.3 ± 2.8
c
 >5 
IP 149.6 ± 6.1
d
 - 
YPYY 194.4 ± 13.0
e
 > 10 
LPL 241.4 ± 11.4
f
 - 
YPY 243.7 ± 2.8
f
 - 
LPLPL 325.0 ± 15.2
g
 - 
YP 658.1 ± 8.0
h
 >5 
LP 712.5 ± 11.0
h
 - 
YY - >5 
IQY - - 
Trolox (× 10
3
) nd 17.2 ± 5.5 
 
*Values represent mean IC50 values ± confidence interval (P = 0.05), n=3. Values with different 
superscript letters are significantly different (P < 0.05). 
nd: not determined, -: no activity detected. 
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Table 2 Concentration of milk protein-derived peptides pre- (control) and post-hydrolysis with dipeptidyl 
peptidase IV (DPP-IV) following incubation at 37C for 18 h at a low (1 U: 1 g peptide) and high (10 U: 1 g 
peptide) enzyme to substrate ratio (E: S). 
 
Parent peptide Predicted sequences post 
DPP-IV hydrolysis 
Peptide or amino acid concentration 
(µM) 
  Control Low E:S High E:S 
IPI (diprotin A) IPI 0.868 ± 0.001 0.854 ±0.002 0.801 ± 0.047 
 IP nd nd 0.072 ± 0.002 
 I nd 0.020±0.017 0.076 ± 0.043 
LPYPY LPYPY 0.408 ± 0.001 0.360 ± 0.001 0.172 ± 0.021 
 LP nd 0.036 ± 0.001 0.182 ± 0.064 
 YPY nd 0.034 ± 0.001 0.192 ± 0.001 
 YP nd nd 0.042 ± 0.001 
 Y nd nd 0.052 ± 0.001 
LPLPL LPLPL 0.468 ± 0.012 0.288 ± 0.001 0.099 ± 0.001 
 LPL nd 0.156 ± 0.002 0.256 ± 0.001 
 LP nd 0.100 ± 0.001 0.487 ± 0.003 
 L nd nd nd 
IPIQY IPIQY 0.450 ± 0.001 0.450 ± 0.001 0.264 ± 0.001 
 IP nd 0.026 ± 0.001 0.158 ± 0.001 
 IQY nd 0.023 ± 0.001 0.162 ± 0.001 
YPYY YPYY 0.441 ± 0.001 0.420 ± 0.001 nd 
 YP nd 0.074 ± 0.001 0.385 ± 0.001 
 YY nd 0.078 ± 0.001 0.397 ± 0.001 
LPL LPL 0.817 ± 0.004 0.801 ± 0.003 0.106 ± 0.055 
 LP nd 0.076 ± 0.002 0.471 ± 0.002 
 L nd nd nd 
YPY YPY 0.501 ± 0.001 0.446 ± 0.047 nd 
 YP nd 0.037 ± 0.024 0.445 ± 0.001 
 Y nd 0.048 ± 0.001 0.430 ± 0.001 
PI PI 1.171 ± 0.004 1.208 ± 0.002 1.239 ± 0.001 
IQY IQY 0.506 ± 0.001 0.469 ± 0.001 0.492 ± 0.001 
 
nd: not detected 
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Table 3 Concentration of milk protein-derived peptides inducing 50 % inhibition (IC50) of dipeptidyl peptidase 
IV (DPP-IV) pre- (control) and post-hydrolysis of the milk protein-derived peptides with DPP-IV following 
incubation at 37C for 18 h at a low (1 U: 1 g peptide) and high (10 U: 1 g peptide) enzyme to substrate ratio (E: 
S). 
 
Compound DPP-IV IC50
*
 
 Control Low E:S High E:S 
IPI (diprotin A) 2.9 ± 0.2
a 3.3 ± 0.1a 4.4 ± 0.3b 
IPIQY 26.7 ± 0.6
c 31.1 ± 0.3c 40.4 ± 0.4d 
LPYPY 90.8 ± 2.8
e 89.7 ± 7.7e 124.1 ± 23.3f 
LPL 186.8 ± 3.1
g 195.8 ± 3.5g,h 542.2 ± 9.1k 
YPYY 207.9 ± 9.2
g,h 238.3 ± 48.1h,i 523.4 ± 31.9k 
YPY 282.0 ± 26.8
j 387.0 ± 40.2j 783.7 ± 50.6l 
LPLPL 358.4 ± 15.6
j 271.6 ± 18.6i 246.7 ± 66.5h,i 
 
*
Values represent mean IC50 values ± confidence interval (P = 0.05), n=3. Values with different 
superscript letters are significantly different (P < 0.05). 
